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Introduction Results
Bladder cancer is the fifth most common cancer in men Patient characteristics 
and the seventh in women. Combination regimens con­
taining cisplatin have produced response rates in 50%- There were 15 males and 4 females with a median age of 
70% of patients with complete responses in 20%-30% [1]. 64 years (range 54-77 years), and a median WHO perfor- 
Lobaplatin (1,2-diamminomethylcyclobutane-plati- mance status 1 (0-2). The primary site was bladder in 16 
num (II) lactate, D-19466) is a third generation plati- patients, renal pelvis in two, renal pelvis 4- ureter in one. 
num analogue. It is water soluble and stable and may not Twelve patients had prior chemotherapy including cis- 
be cross-resistant with cisplatin [2, 3]. A favorable tox- platin or carboplatin in seven, and three had prior RT. 
icity profile and similar efficacy to cisplatin stimulated a Measurable disease sites were the primary tumor in 
phase II study in patients with advanced urothelial tract seven patients, lymph nodes in 21, lung in seven, liver in
tumors. lour and bone in two.
Response
Patients and methods
Twenty-two patients were entered in the trial, of whom
Patients with histologically proven bidimensionally measurable meta- three were ineligible. Two because they had received two
static or locally advanced TCC o f  the urinary tract were eligible.
Patients with unresected carcinoma o f  the ureter or renal pelvis were 
excluded. Patients may have had only one prior chemotherapy regi-
previous lines of chemotherapy, and one because the 
performance status was 3 and no creatinine clearance
men, w h o  performance status ^ 2 ,  age <  75 years, creatinine clear- was available prior to entry. Therefore, 19 patients were 
ance 5=40 mi/min, bilirubin «g 35 micromoi/l, granulocytes > 2 0 0 0  eligible. Two patients were inevaluable for response. One
ce l ls /m m \ platelets > 125,000 ce lls /m m 1, and clinically normal audi­
tory function.
Lobaplatin was supplied by ASTA Medica, Germany, and given at 
50 mg/m" i.v. every three weeks. Drug was continued until develop- 
ment o f  progressive disease. D ose modification to 60 mg/m* (nadir
patient never received lobaplatin due to a myocardial 
infarction. Another patient had an early death caused by 
a CVA due to thrombosis.
The total number of cycles delivered to 18 patients
>50,000 and granulocytes >1,000) or dose reduction to 40 mg/m2 was 50. The median number of cycles administered was
(treatment day platelets < 100,000 or granulocytes <  1,500) were per- 2 (range 0.6  cycles). Of 17 evaluable patients, tWO had a
mitted in subsequent cycles.
For a creatinine clearance ^ 4 0  ml/min, 100% of the dose was 
given. For < 4 0  ml/min, lobaplatin was withheld. Patients were evalu­
able for response if they had received at least two treatment courses.
: course were considerese patients progressive i 
as in progression. Response was evaluated after every two cycles of 
treatment. A  partial response was defined as at least a 50% reduction 
of the bidimensionally measurable disease parameters, determined by 
two observations not less than four weeks apart.
The protocol was conducted according to the Helsinki declaration.
confirmed partial response, one in lymph nodes and the 
other in the skin for 27+ weeks and 20 weeks. Five 
patients were stable. One patient, with a creatinine clear­
ance of 48 and no prior treatment had a PR in retroper­
itoneal lymph nodes and bladder. He was hospitalized 
with a platelet count of 5,000 cells /mm3 after two cycles 
of lobaplatin. He was subsequently treated with M-VAC, 
without a repeat CAT scan at one month, and was
Written or oral informed consent was attained according to the guide- considered as stable. Thus, 2 of 17 (12%; 95% Cl
lines in each participating institution. 0%~-30%) patients had a PR and 5 of 17 (29%; 95% Cl
8%- 50%.) stable disease. Of note, patients who
6 9 6
Table 1. Hematological toxicity.
WHO grade 0 (%) 1 (%) 2 (%) 3 (%) 4 ('Mi)
White blood cells 3(16) 1 (6) 4(22) 9 (50) 1 (6)
Granulocytes 3(17) 4 (22) 6 (33) 5 (28)
Platelets 1 (6) 1(6) 4 (2 2 ) 12(67)
Hemoglobin 2 (1 1 ) 2(11) 3(16) 8 (46) 3(16)
Table 2. Non hematologic side effects.
WHO grade 0 (%) 1 (%) 2 (%) 3 (%) 4 (%)
Nausea/vomiting 6(33) 3 ( 17) 4 (22) 4 (22) 1 (6)
Diarrhea 16(89) 1(6) 1 (6)
Liver 15(83) 1 (6) 1 (6)
Renal 16(89) 2(11)
Pulmonary 17(94) I (6)
Drug fever 14(78) 2(11) 1 (6) 1 (6)
Infection 16(89) 2(11)
Mucositis 15(83) 1(6) 2(11)
Neurotoxicity 13(71) 1 (6) 3(17) 1 (6)
Ototoxicity 17 ( 94) 1 (6)
ovarian cancer [7], in testis cancer, and in esophageal 
tumors [8].
The present study was closed due to prohibitive 
thrombocytopenia, although 2 of the 17 (12%) evaluable 
patients obtained a PR. Of note, neither of these two 
patients had had prior carboplatin or cisplatin. The 
majority of patients entered into this study had therapy 
with a prior analogue. In a brief report of five patients
with advanced TCC, treated with the combination of
i'
lobaplatin, methotrexate and vinblastine (LMV), the 
toxicity profile was acceptable [9].
The toxicity profile of lobaplatin resembles that of 
carboplatin, and consists of thrombocytopenia and leu­
kopenia. In the present study, it was impossible to 
correlate creatinine clearance to thrombocytopenia. In 
retrospect, this trial should not have been conducted in 
this pre-treated patient population and should have 
excluded patients with low creatinine clearance upon 
entry. In conclusion, lobaplatin showed limited activity 
in this patient population.
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